Skip to main content
SCANCELL HOLDINGS PLC logo

SCANCELL HOLDINGS PLC — Investor Relations & Filings

Ticker · SCLP ISIN · GB00B63D3314 LEI · 2138008RXEG856SNP666 IL Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2013-07-23 Director's Dealing
Country GB United Kingdom
Listing IL SCLP

About SCANCELL HOLDINGS PLC

https://www.scancell.co.uk/

Scancell Holdings PLC is a clinical-stage company developing novel active immunotherapies for the treatment of cancer. Its approach focuses on enhancing long-lasting, tumor-specific immunity to address significant unmet needs in oncology, particularly for hard-to-treat cancers. The company leverages its proprietary technology platforms, Immunobody®, Moditope®, and AvidiMab™, to create targeted, off-the-shelf therapies. The Immunobody® platform generates DNA-based immunotherapies, with its lead candidate, iSCIB1+, targeting advanced melanoma. The Moditope® platform develops peptide-based therapies, with a lead product showing encouraging Phase 2 data in a broad range of solid tumors. Scancell aims to deliver treatments that are safe, effective, easily administered, and accessible to patients.

Recent filings

Filing Released Lang Actions
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is an RNS announcement dated July 23, 2013, titled 'Director Shareholdings'. It explicitly details the purchase of ordinary shares by certain Directors of Scancell Holdings Plc on July 22, 2013, including the number of shares purchased and the price. This content directly matches the definition of 'Director's Dealing' (insider trades by executives). Therefore, the appropriate filing code is DIRS.
2013-07-23 English
Second Price Monitoring Extn
Regulatory Filings Classification · 99% confidence The document is very short (1231 characters) and contains an RNS Number ('7701J') and the source 'The company news service from the London Stock Exchange'. The content describes a 'Second Price Monitoring Extension' related to trading activity, which is a specific, non-standard regulatory event notification. Since it is a direct, brief announcement from the exchange's news service (RNS) that doesn't fit the definitions for financial reports (10-K, IR, ER), management changes (MANG), or specific shareholder actions (DIV, DVA), the most appropriate classification is the general regulatory announcement fallback category, RNS.
2013-07-19 English
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1189 characters) and contains the header 'RNS Number : 7691J'. The content describes an extension of the 'Price Monitoring Extension' for a security's closing auction call, which is a specific operational announcement related to trading on the London Stock Exchange. This type of brief, operational market announcement that doesn't fit into specific financial reporting categories (like 10-K, ER, or DIV) is best classified under the general regulatory announcement category, RNS (Regulatory Filings). It is not a report itself, but a notification about market mechanics.
2013-07-19 English
Research Update
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement disseminated via the Regulatory News Service (RNS). The content discusses an update on a clinical study (SCIB1 Study Update) for a drug, detailing patient recruitment issues and future trial plans. This is a specific operational update concerning clinical trials and company progress, not a full financial report (10-K, IR), a formal earnings release (ER), or a management discussion (MDA). Since it is a general, time-sensitive announcement distributed through the official regulatory news channel (RNS) that doesn't fit neatly into other specific categories like Director's Dealing (DIRS) or Dividend Notice (DIV), the most appropriate classification is the general regulatory filing category.
2013-07-12 English
Annual Financial Report
Report Publication Announcement Classification · 99% confidence The document is very short (1134 characters) and explicitly states: 'The Company announces that its annual report and accounts for the financial year ended 30 April 2013 have been posted to shareholders... and a copy is available on the Company's website.' This structure—announcing the publication of a report rather than containing the full report itself—fits the definition of a Report Publication Announcement (RPA). It is not the full 10-K or AR, but a notice about them. The presence of an RNS Number further suggests it is a regulatory announcement about a report release.
2013-07-10 English
Proposed Firm Placing and Open Offer
Capital/Financing Update Classification · 98% confidence The document is an RNS announcement (RNS Number : 8615I) dated July 9, 2013, detailing a 'Proposed Firm Placing and Open Offer and Notice of General Meeting'. This announcement describes a plan to raise capital (£6.5 million) through issuing new shares and calls for a General Meeting for shareholder approval. This clearly falls under financing activities and corporate governance related to a shareholder vote. The key elements are: 1) Announcement of a capital raise (Placing and Open Offer), which aligns with 'Capital/Financing Update' (CAP). 2) It explicitly includes a 'Notice of General Meeting', which relates to shareholder voting. Since the primary purpose is announcing the fundraising and the associated meeting to approve it, 'CAP' is the most fitting primary category for the financial action being taken. It is not a full 10-K, an ER, or a simple DIV notice. It is a specific announcement about a capital raising event.
2013-07-09 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.